APYX
Apyx Medical Corporation
APYX has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over APYX overall, supported by stronger fundamentals and stronger modeled upside.
APYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
APYX's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
APYX PE Valuation
APYX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
APYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect APYX's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
APYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.18 |
| Q2 2026 | -$0.20 | +$0.26 |
| Q1 2026 | -$0.22 | +$0.34 |
| Q4 2025 | -$0.27 | +$0.41 |
| Q3 2025 | -$0.37 | +$0.46 |
| Q2 2025 | -$0.46 | +$0.36 |
| Q1 2025 | -$0.56 | +$0.10 |
| Q4 2024 | -$0.68 | -$0.14 |
APYX is still losing money, but far less than before: $0.19 per share over the past year, against $0.83 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over APYX on earnings quality, reporting a profit while its opponent remains loss making.
APYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14M | +9% |
| Q2 2026 | $13.9M | +22% |
| Q1 2026 | $12.5M | +32% |
| Q4 2025 | $19.2M | +35% |
| Q3 2025 | $12.9M | +12% |
| Q2 2025 | $11.4M | -6.4% |
| Q1 2025 | $9.4M | -7.9% |
| Q4 2024 | $14.2M | -3% |
APYX's revenue has grown year over year for five quarters in a row: $14M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.1% | +2.4 points |
| Q2 2026 | -13% | +9.6 points |
| Q1 2026 | -7.3% | +25 points |
| Q4 2025 | 0.1% | +22 points |
| Q3 2025 | -6.5% | +25 points |
| Q2 2025 | -23% | +23 points |
| Q1 2025 | -32% | +32 points |
| Q4 2024 | -21% | +18 points |
APYX's operating margin was −4.1% last quarter, up 2.4 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over APYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over APYX on profitability, with a higher operating margin.
APYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.9M | +$2.2M |
| Q2 2026 | -$3.6M | -$2.1M |
| Q1 2026 | -$632K | +$125K |
| Q4 2025 | -$2.8M | +$377K |
| Q3 2025 | -$4.1M | +$538K |
| Q2 2025 | -$1.5M | +$3.1M |
| Q1 2025 | -$757K | +$5.6M |
| Q4 2024 | -$3.2M | -$877K |
APYX has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over APYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
APYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +195K shares |
| 1 year | +8.1% | +3.3M shares |
| 3 years | +27% | +9.4M shares |
| 5 years | +28% | +9.7M shares |
| Available history | +29% | +10M shares |
APYX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
APYX Net Leverage
APYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
APYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 28.7 | Neutral |
APYX's weekly RSI is 44 (neutral) and its Stochastic is 29 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
APYX PE vs Healthcare Sector
APYX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
APYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 7.8% above |
| 20 week MA | $3.24 | 11% below |
| 50 week MA | $3.58 | 19% below |
| 100 week MA | $2.77 | 4.3% above |
| 200 week MA | $2.73 | 5.9% above |
APYX's trend is mixed: it's above three of its five weekly moving averages, and 5.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over APYX on trend strength, trading above more of its moving averages.
APYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.23 | $7.04 | -14% |
| 2021 | $7.04 | $13.1 | +86% |
| 2022 | $13.1 | $1.99 | -85% |
| 2023 | $1.99 | $2.62 | +32% |
| 2024 | $2.62 | $1.64 | -37% |
| 2025 | $1.64 | $3.44 | +110% |
| 2026 YTD | $3.44 | $2.89 | -16% |
APYX's yearly returns have swung widely, from +110% in 2025 to −85% in 2022. It's down 16% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over APYX on returns for 2026, with the stronger performance.